Saturday 17 October 2026
Export GTBP’s income statement to Excel — free account
GT Biopharma, Inc.
GTBP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.
7.03
0.33
−4.48%
Follow GTBP
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 12,241.21 | 1,530.15 | 295.80 | 33.15 | 39.78 | 88.80 | 26.28 | 5.40 | 1.72 | 0.54 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 566,156.13 | 40,135.88 | 2,983.48 | 492.15 | 392.70 | 591.99 | 112.20 | 33.00 | 10.66 | 3.85 | |||||
| People | |||||||||||||||
| People | Employees | 2 | 5 | 3 | 2 | 3 | 8 | 2 | 2 | 1 | 1 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | |||||
| EBT | 10 | (144) | (259) | (39) | (28) | (58) | (21) | (8) | (13) | (28) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | 10 | (144) | (259) | (39) | (28) | (58) | (21) | (8) | (13) | (28) | |||||
| Depreciation | 3 | 5 | 10 | 1 | 0 | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | 3,327,385.00 | (109,037.60) | (65,882.20) | (8,554.47) | (4,842.34) | (1,546.55) | (495.50) | (141.00) | (173.50) | (167.00) | |||||
| Cash flow | 0.00 | (4,176.92) | (2,737.69) | (813.11) | (1,252.07) | (416.16) | (358.05) | (164.23) | (170.01) | (58.57) | |||||
| Capex | 0.00 | (3.08) | (9.23) | 44.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | 0.00 | (4,180.00) | (2,746.92) | (768.67) | (1,252.07) | (416.16) | (358.05) | (164.23) | (170.01) | (58.57) | |||||
| Book value | 0.00 | 193,606.92 | 2,915.38 | (4,291.11) | (5,074.66) | 584.27 | 276.09 | 138.70 | (22.00) | 26.24 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (2) | (5) | (11) | (4) | (7) | (16) | (15) | (9) | (13) | (13) | ||||
| Capex | — | 0 | 0 | 0 | — | — | — | — | — | — | |||||
| Free cash flow | (2) | (5) | (11) | (3) | (7) | (16) | (15) | (9) | (13) | (13) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | (19) | (2) | (14) | (19) | (29) | 22 | 12 | 7 | (2) | 6 | ||||
| Total debt | 11 | 0 | 11 | 13 | 26 | 0 | 0 | — | — | — | |||||
| Net debt | 11 | (1) | 11 | 13 | 21 | (32) | (17) | (14) | (4) | (7) | |||||
| Shareholders’ equity | (19) | 252 | 11 | (19) | (29) | 22 | 12 | 7 | (2) | 6 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | 24,729.11 | (113.35) | (185.29) | (299.65) | (934.32) | (306.70) | (85.41) | (49.26) | (143.53) | (558.42) | ||||
| ROIC | 0.00 | (33.74) | (710.97) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (28.11) | (123.88) | (197.06) | 972.88 | 116.09 | 1,541.48 | (124.15) | (79.10) | (453.55) | (1,674.31) | |||||
Negative figures in brackets.
Fiscal years to Dec 2015 · latest quarter Dec 2015
Charts ten years each
GT Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AKTX Akari Therapeutics PLC | $15.5M | — (loss-making) | — | — | n/m | +4.51% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $15.3M | — (loss-making) | — (loss-making) | +2.75% (above 0%: growing) | n/m | −97.84% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $15.3M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| GTBP GT Biopharma, Inc. | $15.2M | — (loss-making) | — | −100.00% (below 0%: shrinking) | n/m | −41.34% (below 0%: shrinking) | 0.00% | 0.00% | |
| DARE Dare Bioscience, Inc. | $14.6M | — (loss-making) | — (loss-making) | +984.43% (above 0%: growing) | n/m | −30.23% (below 0%: shrinking) | (70.56%) | (1,582.93%) | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | Compare |
| CNSY Cerenome, Inc. | $14.3M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| TVRD Tvardi Therapeutics, Inc. | $14.3M | — (loss-making) | — (loss-making) | +20.33% (above 0%: growing) | n/m | −57.26% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $15.0M | — | — | −33.84% | — | −44.36% | 40.86% | 0.00% |
GT Biopharma, Inc. (GTBP) key facts
- GT Biopharma, Inc. (GTBP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, GTBP traded at $7.03, a market capitalization of $15.2 million.
- Return on equity was −1,674.3% and debt-to-equity 0.00.